CAMBRIDGE, Mass. — Enveric Biosciences said preclinical data for its lead drug candidate, EB-003, showed a rapid reduction in conditioned fear response in a model of post-traumatic stress disorder, supporting continued development of the treatment for PTSD and other neuropsychiatric conditions.
The Cambridge-based biotechnology company is developing EB-003 as a neuroplastogenic small-molecule therapy for psychiatric and neurological disorders. The candidate is designed as a dual modulator of the 5-HT2A and 5-HT1B receptors.
Enveric said a single dose of EB-003 significantly reduced context-induced freezing behavior one hour after dosing in a validated preclinical PTSD model. The company said the result suggests EB-003 may have potential to reduce conditioned fear response, a key feature studied in PTSD models.
The company also pointed to increased federal attention on psychedelic-inspired therapies, citing President Donald Trump’s April 18, 2026, executive order supporting research into psychedelic therapies for mental health conditions, including PTSD.
“In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression,” Trump said.
Health and Human Services Secretary Robert F. Kennedy Jr. also cited the need for additional options for patients who do not respond to existing treatments.
“At the same time, millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments,” Kennedy said.
Joseph Tucker, Ph.D., CEO of Enveric Biosciences, said the company believes EB-003 could fit within existing treatment approaches while avoiding some of the logistical challenges associated with traditional hallucinogenic psychedelic therapies.
“We believe Enveric’s portfolio of neuroplastogenic compounds, such as EB-003, is well positioned to meet the challenges recognized by regulators and provide therapeutic solutions that fit within existing patient treatment approaches while avoiding real-world limitations of delivering traditional hallucinogenic psychedelic therapies, which may require specialized clinical infrastructure,” Tucker said.
EB-003 is designed to combine partial agonism of the 5-HT2A receptor with agonism of the 5-HT1B receptor. Enveric said the approach may support neuroplasticity while affecting signaling pathways tied to emotional regulation and stress response.
“Enveric’s EB-003 findings in a model of PTSD highlight the potential importance of targeting both neuroplasticity and mood signaling pathways,” Tucker said. “We believe EB-003’s combined activity at 5-HT2A and 5-HT1B receptors may offer a differentiated approach to promoting neuroplasticity while restoring key signaling pathways involved in emotional regulation and stress response.”
The company said prior studies have linked reduced 5-HT1B receptor expression and function in key brain regions with more severe PTSD symptoms, comorbidity with major depressive disorder and greater lifetime trauma burden. Activation of 5-HT2A receptors has been associated with increased neuroplasticity in brain regions involved in cognition, emotional regulation and decision making.
Enveric said those mechanisms may support potential therapeutic benefits in PTSD and other neuropsychiatric disorders.
